Abstract

SOSA LIPRANDI¹, Alvaro et al. Monitoring of aldosterone blockade. Insuf. card. [online]. 2013, vol.8, n.2, pp.70-76. ISSN 1852-3862.

Blocking the adverse effects of the renin-angiotensin-aldosterone system has been a major focus in the development of drugs for the treatment of cardiovascular disease in the last 30 years. Plasma aldosterone levels transiently decrease after initiation of treatment with inhibitors of angiotensin converting enzyme. In two consecutive meetings, 50 opinion leaders met to discuss critically the current evidence. The present document reflects the consensus of the subject: "Monitoring of aldosterone blockade." In the last decade, it has been shown that aldosterone have detrimental effects on the cardiovascular system, endothelial dysfunction, hypertrophy, fibrosis and cardiovascular inflammation, the effects are independent of angiotensin II. To monitor the different effects of aldosterone drugs, we must consider an algorithm, stating: pretreatment baseline assessment, intra-treatment assessment, contraindications and adverse effects. The search for clinical response and drug monitoring using biomarkers will allow us to assess the evolution of the patient and the desired effect of the drug.

Keywords : Blocking aldosterone; Monitoring; Spironolactone; Eplerenone.

        · abstract in Spanish | Portuguese     · text in Spanish     · Spanish ( pdf )